China Healthcare Select

On June 15, TriApex Laboratories Co., Ltd., which owns around 20,000 laboratory monkeys, submitted a new application for main board listing on the Hong Kong Stock Exchange. According to Frost & Sullivan statistics based on 2025 revenue, TriApex Laboratories ranks first in China's non-clinical research segment for cardiovascular and metabolic diseases and third among domestic CROs specializing in pharmaceutical efficacy studies. The company was co-founded in 2008 by Jiangsu Institute of Materia Medica and Chen Mailin, a Nanjing real estate developer. Dr. Zhang Xuefeng, a pharmacology specialist, joined the firm in 2010. In 2011, Chen Mailin and his wife held 100% equity, kicking off the integration of capital and technical capabilities. TriApex Laboratories was listed on the National Equities Exchange and Quotations (NEEQ) in 2016, and delisted in 2021.

Abogen Biosciences has launched a multicenter Phase III clinical trial for its lyophilized herpes zoster mRNA vaccine, ABO1108, making it the first herpes zoster mRNA vaccine globally to reach this late stage of testing. The vaccine utilizes a proprietary gE protein antigen, base modification technology, and lipid nanoparticle delivery system. A key advantage of ABO1108 is its lyophilized formulation, which remains stable for over two years at standard refrigerator temperatures (2-8°C), addressing logistical challenges associated with current vaccines that require cold storage. Early Phase I and II results demonstrated good safety and tolerability, with high-level immune responses comparable to existing recombinant zoster vaccines. Abogen's accelerated timeline—moving from regulatory approval to Phase III in just seven months—positions the company for a potential first-in-class approval in a competitive market.

Shanghai Juncell Therapeutics Co., Ltd., a biotech company founded in 2019, has filed for an IPO on the Hong Kong Stock Exchange. The company is advancing GC101, the world’s first tumor-infiltrating lymphocyte (TIL) therapy that eliminates the need for high-intensity lymphodepletion or IL-2 administration. In May 2026, GC101 met its primary endpoint in a registrational Phase II trial for advanced melanoma, reducing the risk of progression or death by 57% versus control, earning a Late-Breaking Abstract designation at ASCO 2026—the first solid tumor cell therapy in ASCO history to do so. Juncell plans to submit a BLA to China’s NMPA in Q3 2026, targeting a 2027 market launch as China’s first approved TIL therapy. The company also maintains a diversified pipeline of natural and gene-modified TIL candidates (GC203, GC301, GC304, iGC101) across multiple solid tumors, supported by proprietary DeepTIL™, NovaGMP™, and RiverTIL™ platforms.

On April 27, 2026, China's National Medical Products Administration (NMPA) granted approval to Suzhou Beikang Medical Instrument Co., Ltd. for the country's first pre-implantation genetic testing (PGT) kit targeting thalassemia. Registered as a Class III medical device, the semiconductor sequencing-based kit detects mutations in the HBA1, HBA2, and HBB genes, enabling clinicians to screen IVF embryos for alpha- and beta-thalassemia before implantation. This landmark approval shifts thalassemia prevention from reactive prenatal diagnosis to proactive pre-implantation screening, blocking disease transmission at the source and eliminating the need for late-term pregnancy termination. Developed under the 14th Five-Year Plan National Key R&D Program and fast-tracked through NMPA's priority review channel, the product fills a critical clinical void for millions of carrier couples in southern China's endemic regions, including Guangdong, Guangxi, and Hainan.

Nanochap Electronics Co., Ltd. has unveiled interim GCP trial results for its high-resolution visual brain-computer interface, setting a global record: a patient blind for nearly two decades recognized complex letters one day after implant activation. The breakthrough outpaces conventional artificial retinal devices, which typically require 3–6 months of intensive training to deliver functional vision, marking a key leap from lab research to clinical application. The milestone was delivered by its retinal-pathway E-BCI product, part of the company’s dual-track visual restoration pipeline that also includes a cortical V-BCI offering.

At the Probiota Americas conference in Vancouver, Beijing Bluepha Microbiology Technology Co., Ltd. presented groundbreaking findings from the world's first registered randomized, double-blind, placebo-controlled clinical trial testing a probiotic's ability to promote microplastic excretion in humans. Conducted with Lanzhou University, the trial evaluated Lactiplantibacillus plantarum DT88 (Bluepha Droplastic™ DT88), which was selected from over 10,000 candidate strains through AI-driven screening. Using high-precision Raman spectroscopy to quantify microplastics in stool samples, the study demonstrated three key outcomes: subjects taking DT88 showed total microplastic excretion 3.4 times that of the placebo group; polyethylene (PE) excretion rates were nearly 34 times higher in the DT88 group (P=0.037); and DT88 reversed the concerning accumulation trend of fiber-shaped microplastics, shifting excretion change from -0.32 to +12.46 items/g dry matter. Research published in Environmental Pollution and Frontiers in Microbiology revealed the strain's dual mechanism: physically binding microplastics while repairing gut barrier function through tightened junction proteins and rebalanced cytokines. This milestone represents the first clinical evidence that a probiotic can help the human body flush out accumulated microplastics.